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Abstract 
This study aimed to identify novel loci influencing the antihypertensive response to 
hydrochlorothiazide monotherapy. A genome-wide meta-analysis of blood pressure 
response to hydrochlorothiazide was performed in 1739 white hypertensives from six 
clinical trials within the International Consortium for Antihypertensive 
Pharmacogenomics Studies (ICAPS), making it the largest study to date of its kind. 
No signals reached genome-wide significance (P<5x10-8) and the suggestive regions 
(P<10-5) were cross-validated in two black cohorts treated with hydrochlorothiazide. 
Additionally, a gene-based analysis was performed on candidate genes with 
previous evidence of involvement in diuretic response, in blood pressure regulation 
or in hypertension susceptibility. Using the genome-wide meta-analysis approach, 
with validation in blacks, we identified two suggestive regulatory regions linked to 
GJA1 and FOXA1, relevant for cardiovascular and kidney function. With the gene-
based approach, we identified HSD3B1 as significantly associated with blood 
pressure response (P<2.28X10-4). HSD3B1 encodes the 3beta-HSD enzyme and 
plays a crucial role in the biosynthesis of aldosterone and endogenous ouabain. By 
amassing all of the available pharmacogenomic studies of blood pressure response 
to hydrochlorothiazide, and using two different analytical approaches, we identified 
three novel loci influencing blood pressure response to hydrochlorothiazide. The 
gene-based analysis, never before applied to pharmacogenomics of 
antihypertensive drugs to our knowledge, provided a powerful strategy to identify a 
locus of interest, and which was not identified in the single-SNP analysis due to high 
allelic heterogeneity. These data pave the way for future investigations on new 
pathways and drug targets to enhance the current understanding of personalized 
antihypertensive treatment.  
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INTRODUCTION 
Hypertension is a major global risk factor for stroke, coronary heart disease, 
renal failure, and heart failure, and is the most common chronic disease for which 
medications are prescribed.1 The primary goal of hypertension treatment is the 
reduction of blood pressure (BP), which is strongly associated with the prevention of 
adverse cardiovascular outcomes. However, only approximately 50% of the treated 
hypertensive patients achieve BP control, despite the availability of many classes of 
antihypertensive drugs.2,3 
Thiazide diuretics (TD), inhibitors of the Na+-Cl- symporter, are first line agents 
to treat uncomplicated hypertension as they are effective, relatively safe and well 
tolerated.4 However, as with other anti-hypertensive drugs, there is substantial inter-
individual variation in BP response to TD which can be at least partially attributed to 
genetic differences among individuals.5 Pharmacogenomics, the study of the 
influence of genomic variations on drug response, could be a useful tool to select the 
most effective antihypertensive therapy for an individual, based on genetic profile, 
once replicated drug-gene pairs have been discovered.6 Many groups have 
conducted pharmacogenetic studies on BP response to TD using candidate gene(s) 
7–11 or genome wide association studies (GWAS).12–15 These studies, recently 
reviewed6,16–18, have advanced the knowledge surrounding hypertension 
pharmacogenomics and suggest several genetic variants that may be important 
determinants of response to TD. Nevertheless, only a small percentage of the 
variability in BP response has been explained to date. 
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The International Consortium for Antihypertensive Pharmacogenomics 
Studies (ICAPS) (icaps-htn.org) was created to promote collaboration between 
independent research groups, share knowledge and increase the likelihood for 
genetic discoveries in the field of anti-hypertensive pharmacogenomics.  
Here, we present the largest genome-wide meta-analysis of BP response to 
hydrochlorothiazide (HCTZ, a TD) monotherapy to date in whites with uncomplicated 
hypertension, from six clinical trials included in ICAPS. Because all the currently 
available clinical trials for HCTZ monotherapy in whites with genome-wide genetic 
data were included in our meta-analysis, we used cohorts of black individuals for 
validation. This validation approach among multiple race groups, increases the 
confidence of a functional finding. Moreover, as a useful complement to the GWAS, 
we conducted a gene-based analysis focused on 219 candidate genes with prior 
evidence of involvement in diuretic response or blood pressure regulation, selected 
after a comprehensive literature search.  
 
METHODS 
Study Participants and Inclusion Criteria 
Six study cohorts contributed data to the meta-analysis: the Genetics of Drug 
Responsiveness in Essential Hypertension Study (GENRES)15,19; the Genetic 
Epidemiology of Responses to Antihypertensives study (GERA-1)20; The Milan 
Hydrochlorothiazide study (HCTZ-Milan)13; the Nordic Diltiazem study (NORDIL)9,21; 
the Pharmacogenomic Evaluation of Antihypertensive Responses study (PEAR-1)22 
and the Pharmacogenomics of Hydrochlorothiazide Sardinian Study (PHSS).13 
Detailed information regarding each of six cohorts is included in the Supplement. 
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Across all studies, participants with uncomplicated hypertension were included if 
they had a baseline untreated BP level (i.e., pre-HCTZ treatment) in the hypertensive 
range (systolic BP (SBP) >140 mmHg or diastolic BP (DBP) >90 mmHg). 
Participants previously taking antihypertensive medications underwent a wash-out 
period during which all antihypertensive medications were withdrawn. All participants 
were treated with HCTZ as monotherapy for at least 4 weeks. All participants 
voluntarily signed ethics committee approved informed consent forms and all clinical 
trials were conducted in accordance with regulations set forth by the Declaration of 
Helsinki and local regulatory agencies.  
 
Blood Pressure Response Phenotype 
We used the most precise measure of BP response available for each study. 
In the GENRES and NORDIL studies, BP response was determined as the 
difference between the averaged BP measurements prior to and at the end of HCTZ 
treatment. In the other studies, in which BP was measured at least once between the 
baseline and the end of the treatment period, or by multiple methodologies (e.g., 
office, home, ambulatory BP), we used a single model to take into account all 
available BP measurements, including the intermediate time points and multiple 
methods of measurement. PEAR-1 generated a weighted average of the ofﬁce, 
home, ambulatory daytime and nighttime BP responses calculated on the sums of 
the inverse of the inter-method covariance matrices.23 In the GERA-1, HCTZ-Milan 
and PHSS studies, office BP was measured at one intermediate time point between 
the baseline and the final measurement. These data were fit to a general linear 
model that included baseline BP, sex, age, the first ten principal components and 
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time point. The residuals from this model represent adjusted measurements of 
treatment response. There were typically two such residuals per individual, 
calculated for the two time points, which were combined using a weighted average.  
 
Genotyping and imputation 
Genome-wide genotyping was done on commercially available platforms from 
Illumina or Affymetrix. All genotype data were imputed to HapMap CEU II (build 36, 
version 22), and standard quality control procedures were applied. Details of the 
genotyping and quality control procedures are included in the Supplement. 
 
Statistical Analysis 
Continuous variables are presented as mean and standard deviation, 
categorical variables as numbers and percentages. Between-group comparison of 
continuous variables was performed using one-way analysis of variance (ANOVA) 
and Tukey’s “Honestly Significant Difference" post-hoc test. Categorical data were 
compared between groups using the chi-squared test.  
A total of 1739 white individuals from the six study cohorts are included in the 
GWAS for BP response. Using mach2qtl24 or SNPtest25 software we performed 
linear regressions of the BP response phenotype on SNP dosages adjusting for sex, 
age, pre-diuretic treatment BP and principal components. All GWAS results 
underwent quality control using the EasyQC package26. Genome-wide SNP meta-
analysis was performed using the software METAL27. Details of these analysis 
procedures are included in the Supplement.  
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SNPs with P<5X10-8 were considered genome-wide significant and those with 
P<10-5 were considered suggestive. 
We then performed a trans-ethnic validation in black hypertensives treated 
with HCTZ from the GERA-1 and PEAR-1 studies (Table S1) for the suggestive 
SNPs with P<10-5. We tested the genetic regions harboring the suggestive signals as 
well, since we did not necessarily expect to observe the same SNPs, due to the 
differences in linkage disequilibrium (LD) across the genome between white and 
black populations. Neighboring SNPs were not required to have effects in the same 
direction as, due to differences in LD and allele frequency, neighboring SNPs could 
tag the same unknown causal variant.28 
We conducted a candidate gene-based association analysis in each cohort 
separately using the VEGAS program29 and then performed a meta-analysis of the 
results applying the Fisher’s method30 using the sumlog R function31. We selected 
the candidate genes beginning with the catalogue recently reviewed by 
Padmanabhan et al32 with the inclusion of additional genes found in PubMed by 
using the key search terms “diuretic response,” “hypertension” and “blood pressure 
regulation”. Following this comprehensive literature search, 219 autosomal genes 
(Table S2) were identified based on evidence from candidate studies or GWAS of 
involvement in diuretic response, in BP regulation or in hypertension susceptibility, 
and included in the gene-based analysis. 
 
RESULTS 
Demographic and baseline characteristics of the six cohorts included in the GWAS 
meta-analysis are summarized in Table 1. All participants were white and from the 
USA or Europe. With the exception of GENRES, all cohorts included a majority or 
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exclusively males. Overall, mean age and BMI were significantly different among the 
cohorts. GENRES, HCTZ-Milan and PEAR-1 had similar pre-treatment SBP 
(P=0.09) whereas pre-treatment DBP levels were similar between HCTZ-Milan and 
PEAR-1 (P=0.19) and between GENRES and PHSS (P=0.80).  
 
GWAS Meta-Analysis 
Manhattan and q-q plots for the meta-analysis of SBP and DBP response to HCTZ 
are shown in Figure 1. Although no SNP achieved Bonferroni corrected genome-
wide significance (P< 5x10-8), the q-q plots indicated that the SNPs with P<10-5 
deviated above the straight line, indicating that there is a suggestion of relationships 
between SNPs and BP response. Thus we considered SNPs with P<10-5 as 
suggestive. Accordingly, there were 10 SNPs with suggestive associations with SBP 
response and there were 11 SNPs with suggestive associations with DBP response 
(Table 2). These SNPs were in high LD (r2>0.80) with 34 additional SNPs according 
to HapMap reference (Tagged SNPs, Table 2).  
 
Trans-ethnic replication 
We then assessed the association of suggestive meta-analysis loci (P<10-5) and 
neighboring regions in two black ancestry samples from GERA-1 and PEAR-1. 
Samples characteristics are detailed in the Supplement and in Table S1. GERA-1 
and PEAR-1 black participants had similar mean age and BMI. Pre-treatment DBP 
was higher in GERA-1 group than in PEAR-1 (P=0.004) while pre-treatment SBP 
was not significantly different between the cohorts (P=0.069).  
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In blacks, we identified two regions of interest on chromosome 6 and 14, 
neighboring the identified suggestive SNPs in whites, for SBP and DBP response to 
HCTZ.  
With regard to SBP associations, we identified a signal of interest located in 
the 3’-flanking region of gap junction protein alpha1 gene (GJA1) on chromosome 
6q22.31, where rs11750990 was associated with SBP in the meta-analysis of white 
participants (P=8.11X10-6 and beta=2.44 mmHg per A allele) (Figure 2a, and Table 
2). This variant was nominally associated in the meta-analysis of PEAR1 and 
GERA1 black individuals (P=5-46X10-3) with opposite beta coefficient (beta=-6.17) 
per A allele (Figure 2b). In the same region, a peak of suggestive significance was 
observed in the GERA-1 sample with a different SNP, rs10499113, associated with 
SBP response (P=3.46X10-3 and beta=-3.14 per C allele) (Figure 2c).  
With regard to DBP associations, we identified a signal of interest in the 5’- 
flanking region of forkhead box A1 gene (FOXA1) on chromosome 14q21.1 (Figure 
3). In the meta-analysis of whites, rs177848 was associated with DBP response 
(P=5.8x10-6 and beta=-0.60 per A allele) (Table 2 and Figure 3a). Rs177852, 7.9 kb 
upstream of rs177848, was associated with DBP response in the PEAR-1 black 
cohort (P=1.43X10-3 and beta=-2.95 per C allele) (Figure 3b). 
 
Gene-based Meta-Analysis 
Results of the gene-based analysis are shown in Table S2. Applying a Bonferroni-
corrected significance threshold for gene-based analysis (P<2.28X10-4), we identified 
the hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 
gene (HSD3B1) on chromosome 1p12 as significantly associated with DBP 
response (P= 2.80X10-5) and SBP response (P= 7.5 X10-5) to HCTZ (Table S2). 
9 
 
In the GWAS meta-analysis results for HSD3B1, we observed a cluster of 
SNPs with P≤10-4 associated with BP response to HCTZ (Figure 4, Table S3). For 
SBP response, we identified the 3’-flanking SNP rs7553527 (Beta= -0.86, P= 
3.67X10-5 per C allele) in high LD with the coding SNP rs6203 and the 3’-flanking 
SNP rs10754403 (Beta= -0.83, P= 8.07X10-5 per G allele), which is in LD with 58 
other SNPs within the 3’ to 5’ flanking region (Table S3, Figure 4a). The coding SNP 
rs6203 had a P=2.32X10-3 for DBP response (Table S3, Figure 4b).  
While gene-based analysis for HSD3B1 in blacks was not significant it is 
important to consider that: 1) the LD pattern of the HSD3B1 locus is different 
comparing CEU and YRI HapMap populations (Figure S1); and 2) rs7553527 and 
rs6203 are not present in HapMap data for the YRI population.  
 
DISCUSSION 
This paper describes the largest genome-wide meta-analysis of loci 
influencing the antihypertensive response to HCTZ monotherapy and includes a total 
of 1739 white individuals from six independent cohorts from ICAPS. Using single-
SNP GWAS, we identified two suggestive regulatory regions on chromosomes 6 and 
14, potentially linked to genes relevant for cardiovascular and kidney function. These 
signals were nominally validated in two independent black cohorts. Through a 
complementary candidate gene-based approach, we identified HSD3B1, at a 
significance level taking Bonferroni correction into account, which was not detected 
using the single-SNP GWAS. 
In the genome-wide meta-analysis, no SNP reached the genome wide 
significance level, which is not surprising given the total sample size included in the 
meta-analysis. In fact, despite being the largest HCTZ monotherapy meta-analysis in 
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whites (1739 individuals), we calculated that a sample size ranging from 2860 to 
5571 samples would be required to achieve 80% power at P=5X10-8, assuming an 
expected effect of at least 2 mmHg and an allele frequency ranging from 0.15 to 
0.45.33 The sample size of the present study was powered to find variants with 
effects ≥ 3 mmHg and frequencies ≥ 0.2 whereas, for the suggestive SNPs 
identified, the average effect observed was approximately 1.3 mmHg. 
The suggestive SNPs, as well as SNPs in neighboring regions, that were 
identified in the meta-analysis were tested in two samples of different ancestry.  
The first interesting region for SBP response is located in the 3’-flanking 
region of GJA1. GJA1 encodes the Connexin43 (Cx43), the predominant gap 
junction protein in myocardial and aortic smooth muscle cells with involvement in the 
regulation of cell-to-cell communication and elasticity and contractility of the vascular 
wall.34 The expression of Cx43 was observed to be increased in aortic wall34 and 
muscular artery35 of hypertensive rats and was decreased following exposure to the 
combination of hydralazine-HCTZ and candesartan.35 According to the HaploReg 
database36, the suggestive 3’-flanking region of GJA1 contains eQTLs, transcription 
factor binding sites and histone marks. SNP rs10499113 is reported to be an eQTL 
for GJA1 in skin-sun exposed tissue with C allele carriers exhibiting increased gene 
expression compared to the GG carriers. In the GERA-1 black cohort, the C allele 
was associated with greater SBP response (effect size= -3.1 mmHg and P=3.5X10-
3). Additionally, rs10499113 is in high LD with another eQTL for GJA1, rs2104334 
(not present in the HapMap reference). According to ChiP-Seq experiments from 
ENCODE Project Consortium 2011, in HUVEC cells, rs2104334 maps within a 
probable peak of binding of GATA2 transcription factor, 35 base-pairs upstream the 
GATA2 consensus binding motif. 
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Moreover, in aorta, rs2104334 co-localizes with H3K4me3 histone 
modifications that mark active promoters in chromatin regions and with H3K4me1 
and H3K27ac histone marks associated with enhancers. SNP rs11750990, which we 
identified to be associated with SBP response in the GWAS meta-analysis of whites, 
co-localizes with H3K4me1 and H3K27ac.37 
The 5’-flanking region of FOXA1 was associated with DBP response to HCTZ 
in the GWAS meta-analysis and nominally validated with different SNPs in the 
PEAR-1 black cohort. According to Haploreg annotation36, rs177852, identified to be 
associated with HCTZ response in PEAR-1 black cohorts, is related to FOXA1 
expression in the brain cortex.38 FOXA1, is also expressed in the collecting duct of 
the kidney.39,40 Its putative binding sites were found in the promoters of several 
genes expressed in the urothelium of the renal pelvis including genes encoding the 
vasopressin receptor, several subunits of the Na/K ATPase and E-cadherin.39–41 
Foxa1 has also been identified as a vasopressin induced gene in a differentiated 
mouse clonal cortical collecting duct cell line.42 Furthermore, Foxa1-deficient mice 
develop nephrogenic diabetes insipidus with a defect in renal water reabsorption.40 
For all of the above-mentioned variants, we observed a greater effect size in 
blacks compared to whites. This could be related to the greater antihypertensive 
efficacy of HCTZ in blacks due to their greater volume expansion, salt sensitivity and 
lower renin activity, compared to white hypertensives.43 
Our gene-based meta-analysis provided a very interesting, biologically 
plausible and statistically significant signal that would have remained 
indistinguishable from random noise with the traditional single-SNP GWAS 
approach. Gene-based tests can highlight regions that display substantial allelic 
heterogeneity, defined as the presence of multiple alleles that act through one gene 
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to influence a trait. Furthermore, gene-based tests can increase statistical power by 
combining single variants from GWAS into a gene-based score, which substantially 
reduces the burden of multiple testing.29  
With this approach, we identified HSD3B1. HSD3B1 is expressed as 3β-
hydroxysteroid dehydrogenase (3-beta-HSD) with a crucial role in the biosynthesis of 
hormonal steroids including aldosterone.44 HSD3B1, markedly overexpressed in the 
hypothalamus of Milan hypertensive rats, is involved in endogenous ouabain (EO) 
synthesis in an adrenal medullary–derived cell line (PC12).45 Hypertensive patients 
have elevated circulating EO levels which are positively correlated with higher BP, 
higher plasma Na concentrations and increased proximal tubular reabsorption.46,47 
EO is also higher in patients with kidney failure48, myocardial infarction49 and 
congestive heart failure.50 Multiple studies have described the association of genetic 
variants in HSD3B1 with hypertension or BP variation. The CC genotype at rs6203 
was associated with hypertension51 and higher BP.51–54 This association was 
reported as stronger in males as also confirmed by our single GWAS data (Table 
S4). Additionally, rs3765945 and rs1047303 have been significantly associated with 
SBP.53 The T-C haplotype, established by rs3088283-rs1047303, correlated with 
significantly higher level of aldosterone and BP54 and the G-C-C haplotype of 
rs2236780-rs3765945-rs6203 was related to left ventricular diastolic function.55 
In conclusion, the following can be gathered from our study: (1) this is the 
largest genome-wide meta-analysis of BP response to HCTZ conducted to date; (2) 
while ours is the largest HCTZ meta-analysis conducted to date, our sample size still 
lacked sufficient power; (3) using the single-SNP approach with validation in blacks, 
we identified two suggestive regions linked to the regulation of GJA1 and FOXA1; 
and (4) the gene-based approach, never applied before to pharmacogenomics of 
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antihypertensive drugs to our knowledge, highlights HSD3B1 as a susceptibility gene 
of BP response to HCTZ. This gene was not identified in the single-SNP analysis 
due to high allelic heterogeneity.  
These data pave the way for future research on new pathways and drug 
targets in hypertension toward better-personalized therapeutic approaches. 
 
Perspectives  
Hypertension is a major risk factor for global disease burden and is also the most 
common chronic disease for which medications are prescribed. Pharmacogenomics, 
may represent a useful tool in the future to select antihypertensive therapy with the 
greatest efficacy, based on individual’s genetic profile. This study performed the 
largest pharmacogenomic genome-wide meta-analysis of BP response to HCTZ in 
hypertensive cohorts from ICAPS applying both SNP-based and gene-based 
approaches. Three new biologically plausible loci linked to hypertension and blood 
pressure regulation were identified as markers of BP response to HCTZ. Further 
investigations of the associated regions may enhance the current understanding of 
personalized antihypertensive treatment. 
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Novelty and Significance 
What Is New? 
• this is the largest pharmacogenomics study of BP response to HCTZ. 
• the GWAS SNP-based approach identified two novel loci of BP response to 
HCTZ linked to the regulation of GJA1 and FOXA1. 
• the gene-based approach, never before applied to pharmacogenomics of 
antihypertensive drugs, highlighted HSD3B1 gene as new marker of BP 
response to HCTZ. 
What Is Relevant? 
The identified variants can be considered new biologically plausible loci associated 
with hypertension and blood pressure regulation. 
Summary 
By amassing all the available pharmacogenomic studies of BP response to HCTZ, 
and using two different analysis approaches, we identified three novel loci 
influencing BP response to HCTZ. These data open the way for future research on 
new pathways and drug targets in hypertension toward better personalized 
therapeutic approaches. 
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Figure Legends 
 
Figure 1. Manhattan (a, b) and quantile-quantile (c, d) plots from meta-analysis of 
genome-wide association for systolic (a, c) and diastolic (b, d) blood pressure 
response to hydrochlorothiazide. Each dot signifies a SNP. In the Manhattan plots, 
genomic coordinates are displayed along the X-axis with the negative logarithm of 
the association P-value displayed on the Y-axis. The blue line refers to –log10(P)=5. 
The quantile-quantile plots compare the observed results (–log10(P), X axis) versus 
the theoretically expected values (Y axis). 
 
Figure 2. Local regional plot for chromosome 6q22.31. a) Meta-analysis results for 
white samples b) Replication results in meta-analysis of PEAR-1 and GERA-1 black 
samples c) Replication results in GERA-1 black sample. Each dot signifies a SNP. 
Genomic coordinates are displayed along the X-axis with the negative logarithm of 
the association P-value displayed on the Y-axis. SNPs are colored based on their r2 
with the top signal SNP which has the lowest P-value in the region. 
 
Figure 3. Local regional plot for chromosome 14q21. a) Meta-analysis results for 
white samples b) Replication results in PEAR1 black sample. Each dot signifies a 
SNP. Genomic coordinates are displayed along the X-axis with the negative 
logarithm of the association P-value displayed on the Y-axis. SNPs are colored 
based on their r2 with the top signal SNP which has the lowest P-value in the region. 
 
Figure 4. Local regional plot for HSD3B1 gene. a) SBP and b) DBP meta-analysis 
results for white samples. Each dot signifies a SNP. Genomic coordinates are 
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displayed along the X-axis with the negative logarithm of the association P-value 
displayed on the Y-axis. SNPs are colored based on their r2 with the top signal SNP 
which has the lowest P-value in the region.
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Table 1. Baseline characteristics of study participants * 
Characteristic† GENRES 
‡ 
(n=192)  
GERA-1 
(n=282) 
HCTZ-Milan 
(n=207) 
NORDIL 
(n=381) 
PEAR1 
(n=228) 
PHSS 
(n=449) 
Men/women 192/0 161/121 177/30 148/233 137/91 293/156 
Age, y 50.8±6.2 46.3±8.1 45.7±7.98 61.5±6.7 50.0±9.5 50.9±10.1 
BMI, kg/m2 26.8±2.6 30.9±5.5 26.14±3.05 28.4±4.7 30.3±4.9 27.6±4.0 
Pretreatment SBP, 
mmHg 152.3±12.2 142.4±12.5 149.76±12.5 172.5±15.6 151.8±12.4 158.1±13.0 
Pretreatment DBP, 
mmHg 100.2±6.1 95.4±5.4 98.96±7.76 103.0±4.5 98.1±5.8 100.4±9.9 
Treatment dose 25 mg/day 25 mg/day 12.5 mg/day      at physician discretion 
12.5 mg/day    25 mg/day 25 mg/day 25 mg/day 
Period of treatment 4 weeks 4 weeks 
8 weeks 
(timepoint at 4 
weeks) 
6 months 
8 weeks 
(timepoint at 
2 weeks) 
8 weeks 
(timepoint at 
4 weeks) 
       
Run-in period 4 weeks placebo 4 weeks  Never treated 2 weeks ~ 31 days 
Never 
treated 
 
* BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure 
† Numeric characteristics were presented as mean ± SD; categorical variables were presented as number 
‡ The mean BP level of four placebo treatment periods was used as the baseline ("pretreatment") level 
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Table 2. Meta-analysis results for blood pressure response to hydrochlorothiazide with P<10-5 
Trait Marker Chr Position (bp) Gene/Region Function 
Coded
/other 
alleles
Coded 
allele 
Freq 
Beta  P 
Tagged 
SNPs 
(r2>0.80) 
SBP 
 rs7565329 2 67959340 ETAA1/C1D Intergenic T/C 0.09 -1.7 7.42X10
-6
 rs12642634 4 147205077 ZNF827/LSM6 Intergenic A/G 0.78 1.1 5.15X10
-6
 rs11750990 6 121977301 GJA1/HSF2 Intergenic A/G 0.96 2.44 8.11X10
-6
rs11755230, 
rs11755743, 
rs11752212, 
rs11754717 
 rs2876449 6 141099634 CITED2/NMBR Intergenic T/G 0.03 -2.8 7.06X10
-6
 rs11784910 8 17119626 ZDHHC2 Intronic A/T 0.95 2.31 3.85X10
-7 rs11775427, 
rs11786857 
 rs2925663 8 59424423 FAM110B/UBXN2B Intergenic T/C 0.12 -1.4 7.11X10
-6
rs747401, 
rs733665, 
rs2970756, 
rs2925666 
 rs13253998 8 78697117 PEX2/PKIA Intergenic T/G 0.51 -0.9 6.80X10
-6
rs7960884 12 31251907 FAM60A Intergenic A/G 0.27 1.09 4.23X10-6
 rs16962897 16 82766581 DNAAF1 Intronic A/G 0.12 -1.7 3.25X10
-7
rs1056616, 
rs2288025, 
rs1056612, 
rs3743642, 
rs4150162 
rs4150161 16 82771737 TAF1C Intronic T/C 0.86 1.53 1.02X10-6
28 
 
Trait Marker Chr Position (bp) Gene/Region Function 
Coded
/other 
alleles
Coded 
allele 
Freq 
Beta  P 
Tagged 
SNPs 
(r2>0.80) 
DBP 
rs822127 5 41582716 PLCXD3/OXTC1 Intergenic A/G 0.37 -0.6 6.64X10-6 rs1495757, rs4957159 
rs9370524 6 56327712 COL21A1 Intronic A/G 0.36 0.58 8.51X10-6
rs10951933 7 47873739 PKD1L1 Intronic T/G 0.2 0.75 3.37X10-6 rs10951934, rs17131904 
rs2198596 8 15045137 SGCZ Intronic C/G 0.91 -1.3 7.76X10-7 rs17575278 
rs13256445 8 17106584 ZDHHC2 Intronic T/C 0.85 0.96 1.02X10-6 rs13278086 
rs11784910 8 17119626 ZDHHC2 Intronic A/T 0.95 1.48 3.89X10-7 rs11775427, rs11786857
rs17755650 9 21770037 MTAP  Intergenic T/C 0.9 1.17 5.78X10-6
rs12685849 9 93570641 ROR2 Intronic A/G 0.04 -1.7 9.98X10-6
rs12685213, 
rs3935544, 
rs10992090, 
rs3802377, 
rs3802378, 
rs16907776, 
rs10992095 
rs4757718 11 18761510 PTPN5 Intronic A/G 0.67 -0.6 9.87X10-6
rs177848 14 37173757 TTC6/FOXA1 Intronic/5'-Flanking  A/C 0.59 -0.6 5.81X10
-6 rs1998125, 
rs177829 
rs11657217 17 75323934 ENPP7 Coding C/G 0.69 -0.7 4.50X10-6 rs8081537 
           
SNPs are ranked by chromosome (Chr) and position based on hg18 (NCBI 36) assembly. Tagged SNPs are in high LD (r2>0.80) 
with markers. P refer to the meta-analysis results of GWAS from the 6 ICAPS cohorts. 




